I think you are too high with that stock price estimate of $35-40 Cdn.  Given the outstanding results from the trial, and the lack of current effective treatments, approval was highly likely, so largely priced in to the stock price.  The company already has a market cap of $2.3 billion.  I'd be (pleasantly) surprised if it goes over $25 Cdn Monday.